Filter Results
Clinical Studies
Results filtered:Study status:
Open
Closed for Enrollment
Open
-
Bronchiectasis Research Registry
Rochester, Minn.,
Jacksonville, Fla.
The Bronchiectasis Research Registry is a consolidated database of non-cystic fibrosis (non-CF) bronchiectasis patients from major clinical and research institutions. The goal of the Registry is to support collaborative research and assist in the planning of multi-center clinical trials for the treatment of non-CF bronchiectasis, a progressive, chronic disease of the lungs which afflicts thousands of patients. The Registry is also to be used to provide better insight into the diagnosis, pathophysiology etiologies, and management approaches of the different types of bronchiectasis.
-
CRISPR detection of circulating cell-free Mycobacterium avium complex (MAC) DNA for rapid diagnosis and monitoring of MAC pulmonary disease
Rochester, Minn.
The purpose of this study is to conduct analytic and clinical validation of a CRISPR-based blood test for MAC cellfree DNA as a measure of MAC pulmonary disease activity and treatment response. This biomarker could ultimately be used to guide diagnostic and therapeutic decision-making with regard to MAC pulmonary disease.
-
Patient Reported Outcomes In Patients With Nontuberculous Mycobacterial Pulmonary Disease
Rochester, Minn.
The purpose of this study is e to better understand the trajectory of patient-reported outcomes (PROs), e.g. respiratory symptoms and health-related quality of life (HRQoL), across the entire disease course and measure toxicity and tolerability using patient-reported symptomatic adverse events in treated patients with nontuberculous mycobacterial pulmonary disease (NTM-PD). Secondary objectives are to create a data repository to be linked to future claims, electronic health record, and/or other existing databases and a biorepository of blood samples.
Closed for Enrollment
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Time to First Pulmonary Exacerbation, Safety and Efficacy of ARD-3150 (Dual Release Ciprofloxacin for Inhalation-DRCFI) Compared With Placebo in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Patients With Non-Cystic Fibrosis Bronchiectasis (ORBIT-3)
Rochester, Minn.
The DRCFI treatment will influence the time to first pulmonary exacerbation compared to placebo.
-
Multicenter Randomized Pragmatic Clinical Trial Comparing Two- versus Three-Antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease
Rochester, Minn.
The purpose of this study is to determine whether 2-drug therapy is non-inferior to 3-drug therapy against pulmonary mycobacterium avium complex (MAC) disease, and whether 2-drug therapy is better tolerated than 3-drug therapy.
-
Prospective Phase 0 Study to Investigate Pseudomonas aeruginosa and Staphylococcus aureus Bacterial Load, Patient Characteristics and Exploratory Biomarkers in Adult Patients with Cystic Fibrosis or Non-Cystic Fibrosis Bronchiectasis
Rochester, Minn.
The purpose of this study is to investigate Pseudomonas Aeruginosa and Staphylococcus Aureus bacterial
load, patient characteristics and exploratory biomarkers in adult patients with Cystic Fibrosis or
Non-Cystic Fibrosis Bronchiectasis.
.